OncoMatch/Clinical Trials/NCT06355583
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial
Is NCT06355583 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies EBX-102 for acute lymphoblastic leukaemia.
Treatment: EBX-102 — The goal of this clinical trial is to test the ability to restore gut microbiota to healthier levels in patients with blood cancers scheduled to have stem cell transplant. The main questions it aims to answer are: * Tolerability and acceptability of intestinal microbiota transplantation (IMT) versus placebo (as assessed via patient perspective questionnaires * Changes in gut microbiome diversity across all timepoints * Markers of general health, infective/microbiological and haematological outcomes including, days of fever, admission to intensive care unit, survival, non-relapsed mortality, and incidence of graft-versus-host disease across all time points measured. Participants will be asked at their routine follow up visits to, * Provide stool, urine and blood samples at the scheduled study visits * Complete questionnaires at selected visits * Swallow either Placebo or IMT capsules once at the second study visit which will occur 2 weeks prior to the stem cell transplant (+/-3 days) Researchers will compare IMT capsules and Placebo to investigate the change in gut microbiota diversity.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndrome
Biomarker criteria
Required: ABL1 fusion
Required: BCR fusion
Prior therapy
Must have received: cytotoxic chemotherapy
completed minimum of two cycles of intensive chemotherapy prior to trial enrolment
Must have received: broad-spectrum antibiotics
received broad-spectrum antibiotics within 3 months prior to trial enrolment
Cannot have received: intestinal microbiota transplant
Administration of IMT within 3 months prior to enrolment
Lab requirements
Kidney function
No renal impairment as clinically judged by the Local Investigator
Liver function
No hepatic impairment as clinically judged by the Local Investigator
Patients with renal or hepatic impairment as clinically judged by the Local Investigator [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify